Lymphocyte morphology in a patient receiving CD19 chimeric antigen receptor T-cell therapy for mantle cell lymphoma

[摘要] A 56-year-old male with a diagnosis of relapsed mantle cell lymphomawas recruited to a clinical trial to receive CD19 chimeric antigen receptor (CAR) T-cell therapy (ALLCAR19 trial, NCT02935257). He had previously been treated with multiple lines of therapy including both an autologous and allogeneic haematopoietic stem cell transplant, Ibrutinib and radiotherapy. Prior to commencing lymphodepletion, his bonemarrow biopsy showed 25% infiltration with residual lymphoma.